Work

The ULTRA trial: Transvaginal ovarian ablation in women with infertility related to polyendocrine metabolic ovarian syndrome: clinical outcomes and observed hormonal associations at 12 months

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: STUDY QUESTION Is the novel transvaginal ovarian ablation (TVOA) procedure safe, feasible and effective at inducing ovulation in oligo/anovulatory women with polyendocrine metabolic ovarian syndrome (PMOS)? SUMMARY ANSWER Data from this first-in-human trial provide preliminary evidence that TVOA with a novel system was feasible and not associated with any device-related serious adverse events but was associated with ovulatory and hormonal changes warranting further evaluation in controlled studies in women with PMOS. WHAT IS KNOWN ALREADY Women with PMOS often experience infertility due to oligo/anovulation. If resistant to first-line ovulation induction (OI) medications, women with PMOS are limited to the second-line options of gonadotropin therapy and laparoscopic ovarian drilling, which both have drawbacks for patients and physicians. STUDY DESIGN, SIZE, DURATION The ULTRA study included two parallel single-arm clinical trials; one multi-centre study conducted at six centres in Europe (EU - UK, France and Belgium) and a single-centre study conducted in the United States (US). The planned sample size was up to 35 participants (30 EU and 5 US). These trials were prospectively registered with Clinicaltrials.gov (NCT03760926 and NCT05320289). Trial enrolment occurred between January 2019 and August 2023, with an enrolment pause due to the COVID-19 epidemic. PARTICIPANTS/MATERIALS, SETTING, METHODS The study included women with PMOS aged 18–40 years with a BMI ≤35 kg/m2 (EU) and ≤40 kg/m2 (US) who had failed to respond to first-line ovulation induction (OI) treatments including letrozole (LETZ) and/or clomiphene citrate (CC) with or without metformin. In both trials, failure to respond was defined as failure to ovulate on the highest OI treatment dose. In the US study, inclusion criteria also included failure to conceive on an appropriate dose of OI medication, or if the medication was contraindicated for or declined by participant. PMOS was diagnosed according to the modified Rotterdam Criteria. Study exclusions were having marked obesity (BMI > 35 for EU and > 40 for the US), marked biochemical hyperandrogenism (free androgen index [FAI] > 15), previous ovarian surgery (e.g. LOD, endometriosis surgery, ovarian cysts surgery), or known or suspected periovarian adhesions. Participants underwent ultrasound-guided TVOA. The first five participants in Europe also underwent laparoscopy concurrent with the ablation procedure. After the procedure, serum progesterone was measured weekly until confirmation of ovulation or up to 12 weeks. Women were evaluated and blood was sampled in clinic at 3- and 6-months. Participants were telephoned at 9- and 12-months in both trials and at 24-months in the EU trial to assess menstrual cycle, adverse events, fertility treatments, and pregnancy status. Participants were offered to re-start LETZ/CC at the 3-month follow-up if deemed clinically necessary by the investigator. Outcomes included procedural feasibility, safety, ovulation and serum hormone concentrations. Data are presented by EU and US cohorts. Exploratory analyses were performed with pooled data for illustrative purposes only. MAIN RESULTS AND THE ROLE OF CHANCE There were 32 participants (27 EU, 5 US; mean±SD age, 32.2±3.0 and 31.7±4.7 years respectively; BMI, 28.9±4.2 and 34.3±4.4 kg/m2 respectively) who underwent TVOA. The ablation procedure was successfully completed in 31 of 32 (97%; 95% CI 84–99%) participants (26/27 EU, 5/5 US) overall. Ablation was performed in both ovaries in 26 (81%) participants (22, EU; 4, US) and in a single ovary in six participants (19%, 5 EU, 1 US) either due to small size (volume <8ml) of one ovary (n = 4) or inaccessibility of one ovary (n = 2). Two participants from the first five EU cases sustained a procedure-related serious adverse event (SAE). One SAE was bowel injury related to the laparoscopy, and the other was urinary retention due to the general anaesthesia, but neither was related to the ovarian ablation procedure. There were 31 participants (26 EU, 5 US) available for per-protocol analysis. At 3-months post-procedure, spontaneous ovulation was confirmed in 14/31 (45%; 95% CI 29–62%) of overall participants (11/26 EU, 3/5 US). Eight additional participants ovulated following the reintroduction of first-line OI therapy (6 EU, 2 US). Overall, 22/31 (17/26 EU, 5/5 US) participants (71%; 95% CI 53–84%) achieved ovulation within 12 months post-procedure. Among those who ovulated and attempted conception (21/22), 12 (10 EU, 2 US) conceived within 12 months following the study procedure (12/21, 57.1%; 95% CI 37–76%). All pregnancies were singletons with seven occurring after confirmed recommencement of first-line OI therapy. As all participants of this trial were oligo- or anovulatory for an extended period prior to TVOA even when given oral OI medications, post-ablation ovulation is temporally associated with the intervention but, in the absence of a comparator arm, cannot be attributed to TVOA alone. LIMITATIONS, REASONS FOR CAUTION Limitations include the absence of comparator arm and small sample size inherent to feasibility studies. In addition, there was slight variation in the inclusion criteria between the EU and US centres. The two main differences were the upper BMI limit (35 in EU and 40 in US) and the definition of “failure to respond” to first-line OI therapy. Although the US cohort had an average BMI <35 kg/m2, the median BMI was higher than the EU cohort. In the EU trial, “failure to respond” was defined as failure to ovulate on highest dose, while in the US study, “failure to respond” was defined as failure to ovulate, failure to conceive despite ovulation for at least six cycles, or if the medication was contraindicated for or declined by participant. One of the five US patients was enrolled with a failure to conceive despite ovulation under first-line ovulation induction treatment, while the other four were CC/LETZ resistant. Exploratory analyses on pooled data should be interpreted with caution given the fundamental differences in the composition of the two cohorts. WIDER IMPLICATIONS OF THE FINDINGS These data support the feasibility of performing ultrasound-guided TVOA in a selected population of PMOS women with PMOS-related infertility and did not identify unexpected short-term device-related safety concerns in this small cohort. Observed ovarian phenotype and post-procedure endocrine dynamics may provide biological context for clinical response and inform future hypothesis-driven analyses. FUNDING The study was funded by May Health. DISCLOSURES SA received consultation fees from May Health during the preclinical phase of the ablation device development. However, he has not received any fees for conducting the human clinical trial. KH had contracts with May Health to conduct the US trial and received consulting fees from May Health to develop a subsequent trial. MJ received consultation fees and financial support for attending a conference from May Health. However, MJ has not received any fees for conducting the clinical trial. CW participated on a May Health advisory board, with payment to her institution. All other authors have no conflict of interest to disclose. TRIAL REGISTRATION NUMBER NCT03760926 (https://clinicaltrials.gov/study/NCT03760926; registered 11/21/2018; first patient enrolled 04/17/2019); NCT05320289 (https://clinicaltrials.gov/study/NCT05320289; registered 03/18/2022; first patient enrolled 05/12/2022.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,284
OpenAlex ID: W7236273731
FWCI:
Cites: 11
Cited by:
Related to: 10